Skip to main content
. Author manuscript; available in PMC: 2018 Mar 6.
Published in final edited form as: Cancer Lett. 2013 Sep 14;343(1):14–23. doi: 10.1016/j.canlet.2013.09.010

Fig. 7.

Fig. 7

NSCLC angiogenesis is inhibited by exposure to T-oligo. H358 and SW1573 tumor sections were evaluated by IHC for evidence of angiogenesis. (A) H358 and SW1573 tumors were analyzed for vessel density by staining for the presence of the endothelium specific marker, CD31. A significant decrease in vessel density was observed in both H358 and SW1573 tumors treated with T-oligo. (B) A decrease in vessel density was further validated by totaling the number of intact vessels in 10 microscopic fields. T-oligo treatment decreased total vessel number by 2.2- and 3-fold in H358 and SW1573, respectively. (C) Tumor sections were also stained for the presence of VEGF, which is markedly decreased in T-oligo treated tumors as compared to complimentary oligonucleotide. (D) Additionally, H358 and SW1573 tumors immunostained for TSP-1, a potent inhibitor of angiogenesis, demonstrate a marked increased in TSP-1 after exposure to T-oligo.